Mesenchymal Stem Cell-Derived Exosomes As a Neuroregeneration Treatment for Alzheimer's Disease

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Sep 28

PMID 39335626

Authors

Siddharth Shah

Hadeel M Mansour

Tania M Aguilar

Brandon Lucke-Wold

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is the most prevalent kind of dementia and is a long-term degenerative disease. Pathologically, it is defined by the development of extracellular amyloid-β plaques and intracellular neurofibrillary tangles made up of hyperphosphorylated tau protein. This causes neuronal death, particularly in the hippocampus and cortex. Mesenchymal stem cell (MSC)-derived exosomes have been identified as possibly therapeutic and have promise for Alzheimer's disease due to their regenerative characteristics.

Methods: A systematic retrieval of information was performed on PubMed. A total of 60 articles were found in a search on mesenchymal stem cells, exosomes, and Alzheimer's disease. A total of 16 ongoing clinical trials were searched and added from clinicaltrials.gov. We added 23 supporting articles to help provide information for certain sections. In total, we included 99 articles in this manuscript: 50 are review articles, 13 are preclinical studies, 16 are clinical studies, 16 are ongoing clinical trials, and 4 are observational studies. Appropriate studies were isolated, and important information from each of them was understood and entered into a database from which the information was used in this article. The clinical trials on mesenchymal stem cell exosomes for Alzheimer's disease were searched on clinicaltrials.gov.

Results: Several experimental investigations have shown that MSC-Exo improves cognitive impairment in rats. In this review paper, we summarized existing understanding regarding the molecular and cellular pathways behind MSC-Exo-based cognitive function restoration, with a focus on MSC-Exo's therapeutic potential in the treatment of Alzheimer's disease.

Conclusion: AD is a significant health issue in our culture and is linked to several important neuropathological characteristics. Exosomes generated from stem cells, such as mesenchymal stem cells (MSCs) or neural stem cells (NSCs), have been examined more and more in a variety of AD models, indicating that they may be viable therapeutic agents for the treatment of diverse disorders. Exosome yields may be increased, and their therapeutic efficacy can be improved using a range of tailored techniques and culture conditions. It is necessary to provide standardized guidelines for exosome manufacture to carry out excellent preclinical and clinical research.

Citing Articles

Artificial intelligence (AI)-powered bibliometric analysis of global trends in mesenchymal stem cells (MSCs)-derived exosome research: 2014-2023.

Tsai S, Wan B, Tsai F, Yang J Biomedicine (Taipei). 2025; 14(4):61-77.

PMID: 39777112 PMC: 11703396. DOI: 10.37796/2211-8039.1470.

References

van Velthoven C, Kavelaars A, van Bel F, Heijnen C . Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav Immun. 2009; 24(3):387-93. DOI: 10.1016/j.bbi.2009.10.017. View

Jokar S, Marques I, Khazaei S, Martins-Marques T, Girao H, Laranjo M . The Footprint of Exosomes in the Radiation-Induced Bystander Effects. Bioengineering (Basel). 2022; 9(6). PMC: 9220715. DOI: 10.3390/bioengineering9060243. View

Goetzl E, Schwartz J, Abner E, Jicha G, Kapogiannis D . High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol. 2018; 83(3):544-552. PMC: 5867263. DOI: 10.1002/ana.25172. View

Armstrong R . Risk factors for Alzheimer's disease. Folia Neuropathol. 2019; 57(2):87-105. DOI: 10.5114/fn.2019.85929. View

Lakshmisha Rao Y, Ganaraja B, Murlimanju B, Joy T, Krishnamurthy A, Agrawal A . Hippocampus and its involvement in Alzheimer's disease: a review. 3 Biotech. 2022; 12(2):55. PMC: 8807768. DOI: 10.1007/s13205-022-03123-4. View

eClinicalMedicine . Alzheimer's disease: Still in need of a cure!. EClinicalMedicine. 2021; 39:101146. PMC: 8478681. DOI: 10.1016/j.eclinm.2021.101146. View

Harris V, Faroqui R, Vyshkina T, Sadiq S . Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med. 2012; 1(7):536-47. PMC: 3659719. DOI: 10.5966/sctm.2012-0015. View

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J . Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019; 15(8):1071-1080. DOI: 10.1016/j.jalz.2019.05.002. View

Reubinoff B, Itsykson P, Turetsky T, Pera M, Reinhartz E, Itzik A . Neural progenitors from human embryonic stem cells. Nat Biotechnol. 2001; 19(12):1134-40. DOI: 10.1038/nbt1201-1134. View

10.

Ager R, Davis J, Agazaryan A, Benavente F, Poon W, LaFerla F . Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. Hippocampus. 2014; 25(7):813-26. PMC: 4722865. DOI: 10.1002/hipo.22405. View

11.

Le Gall L, Ouandaogo Z, Anakor E, Connolly O, Butler Browne G, Laine J . Optimized method for extraction of exosomes from human primary muscle cells. Skelet Muscle. 2020; 10(1):20. PMC: 7341622. DOI: 10.1186/s13395-020-00238-1. View

12.

Goetzl E, Abner E, Jicha G, Kapogiannis D, Schwartz J . Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. FASEB J. 2017; 32(2):888-893. PMC: 5888398. DOI: 10.1096/fj.201700731R. View

13.

Chan H, Yanshree , Roy J, Tipoe G, Fung M, Lim L . Therapeutic Potential of Human Stem Cell Implantation in Alzheimer's Disease. Int J Mol Sci. 2021; 22(18). PMC: 8471075. DOI: 10.3390/ijms221810151. View

14.

Paroni G, Bisceglia P, Seripa D . Understanding the Amyloid Hypothesis in Alzheimer's Disease. J Alzheimers Dis. 2019; 68(2):493-510. DOI: 10.3233/JAD-180802. View

15.

Lugli G, Cohen A, Bennett D, Shah R, Fields C, Hernandez A . Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One. 2015; 10(10):e0139233. PMC: 4591334. DOI: 10.1371/journal.pone.0139233. View

16.

Nielsen J, Honore B, Vestergard K, Maltesen R, Christiansen G, Boge A . Shotgun-based proteomics of extracellular vesicles in Alzheimer's disease reveals biomarkers involved in immunological and coagulation pathways. Sci Rep. 2021; 11(1):18518. PMC: 8445922. DOI: 10.1038/s41598-021-97969-y. View

17.

Kim J, Kim D, Kim D, Kim J, Jeong S, Jeon H . Galectin-3 secreted by human umbilical cord blood-derived mesenchymal stem cells reduces amyloid-beta42 neurotoxicity in vitro. FEBS Lett. 2010; 584(16):3601-8. DOI: 10.1016/j.febslet.2010.07.028. View

18.

Goetzl E, Kapogiannis D, Schwartz J, Lobach I, Goetzl L, Abner E . Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB J. 2016; 30(12):4141-4148. PMC: 5102122. DOI: 10.1096/fj.201600816R. View

19.

Musial-Wysocka A, Kot M, Majka M . The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019; 28(7):801-812. PMC: 6719501. DOI: 10.1177/0963689719837897. View

20.

Qiu C, Kivipelto M, von Strauss E . Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009; 11(2):111-28. PMC: 3181909. View